ASKER, Norway, 1st April 2023 – NextPharma, a leading European pharmaceutical Contract Development and Manufacturing Organisation (“CDMO”), is pleased to announce the completion of its acquisition from Takeda of a state-of-the-art chewable tablets manufacturing site in Asker, Norway.
The Asker site, which has approximately 170 employees and a high degree of production automation, has operated for more than 50 years, producing a broad portfolio of strengths and flavours of calcium/vitamin D3 chewable tablets. It will be NextPharma’s centre of excellence for the development and manufacturing of chewable tablet forms, adding to NextPharma’s existing site portfolio of centres of excellence, each specialising in different technologies and product types. With its unique capabilities and deep employee expertise, the site is well-positioned to attract new customers with both product development and commercial manufacturing business.
Bjørn Lie, head of the manufacturing site at Asker comments: “With NextPharma, we are confident that Takeda has chosen a buyer who will help nurture and grow the Asker site. We are all excited about joining the NextPharma team and look forward to working together to drive the long-term development and growth of the business and our people.”
Peter Burema, CEO of NextPharma, comments: “We are excited by the addition of a world-class manufacturing site and a new centre of excellence for chewable tablets to our operational network, allowing us to further broaden our technology offering for both existing and new customers. These technologies, combined with the know-how and expertise of the site’s employees, will continue to benefit patients across the world. On behalf of NextPharma, I welcome our new colleagues, and I am confident that together we will continue to further develop and grow NextPharma as a leading and well-respected European CDMO.”
NextPharma offers specialised CDMO services in oral and topical (including sterile ophthalmic) finished dosage forms to a broad base of global pharmaceutical customers. With this acquisition, NextPharma will continue to provide excellent levels of quality and service delivery to the site’s existing customers, in addition to developing and broadening its technology offering into chewable tablets. The NextPharma and Takeda teams have worked closely together over the past months to ensure a smooth and successful transition.
Eduardo Montanha, Senior Vice President, Head of Small Molecules Operating Unit, Takeda, comments: “We are pleased to have divested the Asker plant to NextPharma, to whom all of our Asker manufacturing employees have transferred. In NextPharma, we believe we have found the most suitable owner for the site, offering a great fit for the Asker facility and team. We sincerely thank the team in Asker for its work and dedication over the past years and for always putting our customers and patients at the centre of what they do. We wish them and NextPharma every success.”
About NextPharma
NextPharma is a leading European pharmaceutical Contract Development and Manufacturing Organisation (“CDMO”) with a footprint spanning five sites in Germany, two in France, one in Finland, Norway and Scotland, and with healthcare logistics services in the DACH region. NextPharma supplies products globally, with nine of its ten sites FDA-approved. With expertise in solids, semi solids and non-sterile and sterile liquids, the company provides services from pharmaceutical development, clinical supplies, scale-up and process validation through to commercial manufacturing for a large range of dosage forms including tablets, capsules, granules, powders, pellets, gels, creams, liquid-filled capsules, softgels, sprays and syrups. Additionally, it provides a wide range of packaging solutions including blow-fill-seal, blisters, bottles, sachets, stick packs and tubes. NextPharma’s expertise and centres of excellence enable it to provide a unique service offering in certain specialised areas including hormonal solids and semi-solids, cephalosporins, penicillins, narcotics, chewable tablets, modified release products, lipid-based formulations (including hormonal and high potent products), as well as paediatric medicinal products. For more information, please visit www.nextpharma.com.
Media Contact NextPharma:
Peter Burema
Chief Executive Officer
peter.burema(at)nextpharma.com
Telefon: +44 203 585 4120
Download: